Greg Herrema to lead next phase of global expansion for biospecimens and biomarkers company
HUNTSVILLE, Ala., Nov. 10, 2023/PRNewswire/ -- Discovery Life Sciences, biospecimen and biomarker specialists, today announced the appointment of Greg Herrema as its new CEO. A leader with more than 20 years of experience in the industrial and life sciences sectors, Herrema will lead Discovery's next phase of expansion. He succeeds Glenn Bilawsky, who announced plans to step down after leading Discovery's transformation into a global provider of biological specimen products and multi-omics laboratory services.
Herrema joins Discovery after a successful career at Thermo Fisher Scientific, where he served as senior vice president and president of the global life sciences company's more than $8 billion laboratory supplies distribution business. He previously ran its biosciences, analytical instruments, scientific instruments and environmental instruments businesses. Herrema began his career at General Electric. He serves on several nonprofit boards focused on land conservation and community engagement.
Glenn Bilawsky, who will remain a member of Discovery's board of directors, stated: "Greg's leadership skills, industry knowledge and commitment to social responsibility make him the ideal candidate to lead Discovery into its next phase. of innovation and growth. I am confident in his ability to lead the company to new heights in our mission to restore hope by accelerating the development of innovative diagnostics and effective treatments to improve care."
Under Bilawsky's leadership, Discovery acquired 13 businesses and advanced internal initiatives that significantly expanded its scientific capabilities and services. The company recently opened its new global headquarters in a state-of-the-art facility housing biospecimen products and multi-omics biomarker and analysis services on the HudsonAlpha Biotechnology Institute campus in Huntsville. Today, Discovery supports more than 750 pharmaceutical, biotechnology and diagnostic companies with their research and development needs.
Greg Herrema, newly appointed CEO of Discovery, said: "I am delighted to join the Discovery Life Sciences team as CEO and am proud to be part of a company at the forefront of advancing scientific research. I am deeply committed to "to work with our talented team to support our customers' pursuit of innovative advances in the life sciences that positively impact lives and communities around the world."
About Discovery Life Sciences
Discovery Life Sciences is the biospecimen and biomarker specialist company. We combine a comprehensive commercial biological sample acquisition and inventory network with excellent multi-omic biomarker service laboratories. Our offerings include genomic, tissue biomarker, proteomic and cell-based services, accelerating the development of novel biomarker-supported therapies and companion diagnostic programs for cancer, infectious diseases and other rare and complex conditions.
Through AllCells, our cell and gene therapy division, we maintain a significant pool of recoverable donors, supplying cryopreserved and fresh human cellular materials for research use only (RUO) and clinical grade to support programs. of cell and gene therapy at any stage of development and scale.
Motivated by leading scientific expertise and innovative application of today's technologies, the Discovery team collaborates with clients to quickly overcome obstacles and achieve results, helping make critical research and development decisions with unmatched speed. We are Science at your Service! For more information, visit www.dls.com.
Photo - https://mma.prnewswire.com/media/2268228/Greg_Herrema_Discovery_Life_Sciences.jpgLogo - https://mma.prnewswire.com/media/1022478/Discovery_LS_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/discovery-life-sciences-anuncia-nuevo-consejero-delegado-301984724.html